These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 24702974)
1. [Pharmacokinetics and pharmacodynamics of ceftaroline]. Grau S; Sorlí L; Luque S Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():15-20. PubMed ID: 24702974 [TBL] [Abstract][Full Text] [Related]
2. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Steed ME; Rybak MJ Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458 [TBL] [Abstract][Full Text] [Related]
3. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion. Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279 [TBL] [Abstract][Full Text] [Related]
5. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792 [TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Vidaillac C; Leonard SN; Rybak MJ Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. Drusano GL J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453 [TBL] [Abstract][Full Text] [Related]
10. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924 [TBL] [Abstract][Full Text] [Related]
11. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Saravolatz LD; Stein GE; Johnson LB Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559 [TBL] [Abstract][Full Text] [Related]
13. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. Riccobene T; Jakate A; Rank D J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097 [TBL] [Abstract][Full Text] [Related]
14. Ceftaroline: a new broad-spectrum cephalosporin. Lim L; Sutton E; Brown J Am J Health Syst Pharm; 2011 Mar; 68(6):491-8. PubMed ID: 21378297 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model. Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630 [TBL] [Abstract][Full Text] [Related]
17. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Sader HS; Flamm RK; Farrell DJ; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950 [TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Poon H; Chang MH; Fung HB Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related]
20. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012). Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]